IL-21/IL-21R blockade is associated with decreased IL-6 and autoantibody production and has shown positive effects in preclinical trials in murine models of lupus and rheumatoid arthritis (65, 66). This evidence concerns the gene IL21R and systemic lupus erythematosus.